Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Harmony Biosciences (NASDAQ:HRMY) has been analyzed by 6 analysts, showing a range of perspectives from bullish to bearish. The average 12-month price target is $52.67, with a high of $56.00 and a low of $52.00. The company has shown strong revenue growth and profitability, but its ROE is below industry benchmarks.
October 02, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harmony Biosciences has received a range of analyst ratings, predominantly bullish, with a 12-month price target average of $52.67. The company shows strong revenue growth and profitability, but its ROE is below industry benchmarks.
The analysis shows a predominantly bullish sentiment among analysts, with a slight increase in the average price target. The company's strong revenue growth and profitability are positive indicators, although the low ROE suggests some challenges. Overall, the news is likely to have a positive short-term impact on HRMY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100